Protocol Ledger

NCT03808922 · Phase III · RECRUITING

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Interventional Phase III clinical trial protocol NCT03808922 sponsored by Ansun Biopharma in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-05-23 Enrollment: 274 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03808922
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)274 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03808922
Protocol FieldVerified Registry Value
NCT IdentifierNCT03808922
Consolidated Lead SponsorAnsun Biopharma
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment274 participants (ESTIMATED)
Registered Start Date2019-05-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI